SanBio Co (JP:4592) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SanBio Co. has completed its second commercial production run of AKUUGO suspension for intracranial implantation, achieving expected yield results. The company anticipates starting shipments by the second quarter of the fiscal year ending January 2026, pending compliance with specification tests. This development is expected to have minimal impact on the current fiscal year’s financial performance.
For further insights into JP:4592 stock, check out TipRanks’ Stock Analysis page.